At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Pevonedistat +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Pevonedistat, Rifampin, and 3 other interventions for Advanced Solid Neoplasm. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Neoplasm
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartAug 2018
Primary CompletionMay 2019
Study CompletionFeb 2021
TodayJul 2026
First PostedApr 3, 2018
Enrollment StartAug 13, 2018
Primary CompletionMay 10, 2019
Study CompletionFeb 28, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.2 years ago
Interventions
Pevonedistatdrug
Pevonedistat intravenous infusion.
Rifampindrug
Rifampin capsules.
Docetaxeldrug
Docetaxel intravenous infusion.
Carboplatindrug
Carboplatin intravenous infusion.
Paclitaxeldrug
Paclitaxel intravenous infusion.